1084 related articles for article (PubMed ID: 15128354)
1. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
2. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
[TBL] [Abstract][Full Text] [Related]
3. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?
Canedo J; Lee SH; Pinto R; Murad-Regadas S; Rosen L; Wexner SD
Colorectal Dis; 2011 Nov; 13(11):1294-8. PubMed ID: 20969715
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients.
Alves A; Panis Y; Bouhnik Y; Pocard M; Vicaut E; Valleur P
Dis Colon Rectum; 2007 Mar; 50(3):331-6. PubMed ID: 17252288
[TBL] [Abstract][Full Text] [Related]
5. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
Marchal L; D'Haens G; Van Assche G; Vermeire S; Noman M; Ferrante M; Hiele M; Bueno De Mesquita M; D'Hoore A; Penninckx F; Rutgeerts P
Aliment Pharmacol Ther; 2004 Apr; 19(7):749-54. PubMed ID: 15043515
[TBL] [Abstract][Full Text] [Related]
6. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
7. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
10. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
[TBL] [Abstract][Full Text] [Related]
11. Steroids and poor nutrition are associated with infectious wound complications in children undergoing first stage procedures for ulcerative colitis.
Markel TA; Lou DC; Pfefferkorn M; Scherer LR; West K; Rouse T; Engum S; Ladd A; Rescorla FJ; Billmire DF
Surgery; 2008 Oct; 144(4):540-5; discussion 545-7. PubMed ID: 18847637
[TBL] [Abstract][Full Text] [Related]
12. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
[TBL] [Abstract][Full Text] [Related]
13. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease.
El-Hussuna A; Andersen J; Bisgaard T; Jess P; Henriksen M; Oehlenschlager J; Thorlacius-Ussing O; Olaison G
Scand J Gastroenterol; 2012 Jun; 47(6):662-8. PubMed ID: 22486168
[TBL] [Abstract][Full Text] [Related]
14. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease.
Myrelid P; Olaison G; Sjödahl R; Nyström PO; Almer S; Andersson P
Dis Colon Rectum; 2009 Aug; 52(8):1387-94. PubMed ID: 19617749
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease.
Bafford AC; Powers S; Ha C; Kruse D; Gorfine SR; Chessin DB; Bauer JJ
J Clin Gastroenterol; 2013 Jul; 47(6):491-5. PubMed ID: 23090048
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of ileocolic resection and right hemicolectomies for Crohn's patients in comparison with non-Crohn's patients and the impact of perioperative immunosuppressive therapy with biologics and steroids on inpatient complications.
Mascarenhas C; Nunoo R; Asgeirsson T; Rivera R; Kim D; Hoedema R; Dujovny N; Luchtefeld M; Davis AT; Figg R
Am J Surg; 2012 Mar; 203(3):375-8; discussion 378. PubMed ID: 22364904
[TBL] [Abstract][Full Text] [Related]
18. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
Ochsenkühn T; Göke B; Sackmann M
Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
[TBL] [Abstract][Full Text] [Related]
19. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
20. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
